+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hepatitis B Drug"

Hepatitis B - Epidemiology Forecast to 2032 - Product Thumbnail Image

Hepatitis B - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
US Hepatitis B Market and Competitive Landscape - 2022 - Product Thumbnail Image

US Hepatitis B Market and Competitive Landscape - 2022

  • Report
  • August 2022
  • United States
From
From
From
From
Antiviral Therapeutics - Technologies, Markets & Companies - Product Thumbnail Image

Antiviral Therapeutics - Technologies, Markets & Companies

  • Report
  • November 2021
  • 620 Pages
  • Global
From
Loading Indicator

The Hepatitis B Drug market is a subset of the Infectious Diseases Drugs market. It is composed of drugs used to treat the hepatitis B virus, a virus that can cause serious liver damage. These drugs are used to reduce the amount of virus in the body, reduce the risk of liver damage, and improve overall health. Common drugs used to treat hepatitis B include interferon, nucleoside analogues, and protease inhibitors. The Hepatitis B Drug market is highly competitive, with many companies offering treatments. Some of the major players in the market include Gilead Sciences, Merck & Co., AbbVie, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more